Osteoporosis is a metabolic bone disorder commonly occurred in aging populations, particularly postmenopausal women and patients who undergo long-term steroid or anti-estrogen therapies. Given the rapid growth of the aging population, the prevalence of bone loss, and the huge medical and healthcare cost involved, demand for alternative approaches for the promotion of bone health is pressing. With the advent of global interest in complementary and alternative medicine and natural products, Chinese medicine serves as a viable source that offers benefits to improve and maintain bone health. This review summarizes the scientific information on the Chinese medicinal herb Ligustrum lucidum and its chemical components as potential therapy for osteoporosis.
Osteopenia (low bone density) and osteoporosis ("porous bone") are metabolic bone disorders commonly occurred in aging populations, particularly postmenopausal women and patients who undergo long-term steroid or anti-estrogen therapies. Although postmenopausal women are at greater risk, osteopenia/osteoporosis can strike at any age of both genders. The disease is characterized by thinning of bones, with reduction in bone mass and bone mineral density, as well as microarchitectural deterioration of the bone tissue due to depletion of calcium and bone protein. The clinical result is loss of bone strength, thus making bone more fragile and vulnerable to fracture, which often happens in the hip, spine, and wrist. Worldwide, osteoporosis is estimated to affect 200 million women, approximately one-tenth of women aged 60 and one-fifth of women aged 70 [1] . Although the overall prevalence of fragility fractures is higher in women, men generally have higher rates of fracture related mortality. The National Osteoporosis Foundation projected that by 2020, 14 million Americans over the age of 50 are expected to have osteoporosis and another 47 million to have low bone mass, accounting for 55% of the population 50 years of age and older [2] .
A comprehensive bone health management plan usually includes non-pharmacologic measures such as balanced diet, adequate calcium and vitamin D intake, exercise and fall prevention, together with pharmacologic therapy [3] . For osteoporosis prevention and treatment, less than ten FDA-approved drugs are currently available. They fall into two major classes, the anti-resorptive and the anabolic drugs. Anti-resorptive medications such as the bisphosphonates (alendronate, ibandronate, risedronate, and zoledronic acid), calcitonin, denosumab (a receptor activator of nuclear factor-κB ligand [RANKL] inhibitor), selective estrogen receptor modulator (raloxifene), and estrogen (with or without progesterone) slow down the process of bone loss; and the anabolic drug such as the recombinant form of parathyroid hormone (teriparatide) enhances bone formation [4] [5] [6] . However, the longterm safety of many of these anti-osteoporosis drugs has posted some concerns; for example, potentially serious adverse effects of bisphosphonate therapy have been reported [7] [8] [9] [10] [11] [12] . Only a small number of investigational drugs are currently in the pipeline of development [13, 14] .
Apart from drug therapy, hormone replacement therapy is effective in increasing bone density and reducing the risk of fracture, and it is an effective regimen for the prevention and treatment of postmenopausal osteoporosis. Nevertheless, the use of estrogenic hormones has been severely limited by concerns for the increased risk of breast, endometrial and ovarian cancers, heart attack, and stroke [15] . Dietary supplementation of calcium and vitamin D is often included as part of the treatment plan, yet calcium and vitamin D alone or in combination are ineffective in reducing fractures in the absence of pharmacologic agents [16, 17] . [18] and Australia [19] indicated that over 50% of osteoporosis patients go for complementary and alternative medicines, with up to 10% seeking treatment from herbal therapy or Chinese medicine. Soy isoflavone [20] [21] [22] [23] , red clover [24] and black cohosh [25] are commonly used by postmenopausal women with or without osteoporosis. Indeed, botanicals prepared as dietary supplements hold promise for use and there is considerable interest because the general population is receptive to the use of natural products for long-term treatment, and the cost for dietary supplements is more affordable to the elderly population.
Studies in Canada
The dried fruit of Ligustrum lucidum Ait. (Oleaceae), known in herbal medicine as "Ligustri Lucidi Fructus" and in Chinese medicine as "Lu-Zhen-Zi", is a tonic drug ("good-for-health") often included in herbal prescriptions for vitalizing the "liver and kidney" functions as well as nourishing the "Yin component" in these organs. It is indicated for "weakness of the loin and knees" [26] , which may represent a symptom of bone deterioration. Indeed, the Chinese medical theory states that "the kidney serves to strengthen the bone" [27] and, therefore, the use of Lucidum fruits as a kidneytonifying agent among the elderly to improve skeletal strength is supported by substantial ethnomedical evidence.
To the best of our knowledge, the first reports on the osteoprotective activity of L. lucidum were published by Zhang et al. [28, 29] . In the studies, an extract of L. lucidum fruits was given to three-month-old ovariectomized rats four weeks after surgical operation and continued for fourteen weeks. Results showed that both bone turnover and calcium balance were improved. Thus, treatment with the plant extract suppressed bone turnover markers such as serum osteocalcin and urinary deoxypyridinoline. It also decreased urinary and fecal calcium excretion as well as increased the bone calcium content. In addition, the mRNA expressions of renal calbindin-D9K and calbindin-D28K were up-regulated. These findings suggested the involvement of both vitamin D metabolism and calcium reabsorption. Indeed, in aged (eleven-month old) female rats treated with the ethanol extract of L. lucidum fruits, serum levels of 1,25-dihydroxyvitamin D 3 and the mRNA expression of duodenal calcium binding protein CaBP-9k were increased; renal CaBP-28K mRNA expression was also upregulated [30] . In a study to investigate whether the plant extract could improve bone properties in aged animals, both sham-and ovariectomized ten-month-old female rats were treated with the extract for 12 weeks, at three levels of dietary calcium contents. The L. lucidum extract significantly improved bone mineral density and content at tibial and femoral diaphysis as well as the lumbar vertebrae (LV-2) in rats fed with diets containing either low calcium (0.1%) or medium calcium (0.6%) level; the biomechanical strength of the tibial diaphysis was also improved [31] . In a similar experiment, eight-week treatment in ovariectomized aged rats also prevented the loss of bone mineral density [32] .
In a retinoic acid-induced osteoporosis rat model, treatment with L. lucidum led to an increase of serum calcium and phosphorus contents, together with lowered alkaline phosphatase and tartrateresistant acid phosphatase levels, as well as improved bone microarchitecture [33] .
When the osteoblast-like UMR-106 cells were treated with the plant extract, increased formation of calcified matrix and increased extracellular calcium and phosphorus deposition were observed. These results suggested that L. lucidum extract could improve bone properties possibly via the enhancement of differentiation and mineralization of osteoblasts [31] . Indeed, in vitro study using human bone marrow mesenchymal stem cells treated with an ethanol extract of L. lucidum displayed stimulatory activity on osteogenic differentiation, evidenced by an increase in alkaline phosphatase activity and shortening of time needed for mineralization. The mRNA expressions of osteoblast differentiation regulatory genes involved in the Wnt signaling, such as β-catenin, bone morphogenetic protein (BMP)-2, cyclin D1, MT1-MMP, osteoprotegerin (OPG) and TBX3, were up-regulated, thus enhancing osteogenesis [34] . The aqueous extract of the same plant materials also demonstrated promoting effects on both human and rat mesenchymal stem cells as shown by enhanced alkaline phosphatase activity, mineralization level, and the expression of osteopontin [35] . In osteoblast-like MC3T3-E1 cells, an extract of L. lucidum increased cell viability and promoted cell differentiation by up-regulating the OPG and RANKL mRNA and protein expressions [36] .
The improved calcium balance after treatment was found to associate, at least in part, with an increase of circulating levels of 1,25-dihydroxyvitamin D 3 via up-regulating the 25-hydroxyvitamin D 1α-hydroxylase activity [37] . At the same time, the renal mRNA expression of 25-hydroxyvitamin D 24-hydroxylase was suppressed [38] . These findings suggested that the protective effects of the ethanol extract on bone could be accounted for by its direct actions on the vitamin D system, including the biosynthesis of 1,25dihydroxyvitamin D 3 and the expression of vitamin D-dependent calcium transport protein expression. In a subsequent study, the plant extract was separated into ethyl acetate-soluble and watersoluble fractions by solvent extraction. The results indicated that the Table 1 : Secondary metabolites in the fruit of Ligustrum lucidum known prior to 2011 (Adopted and translated based on the information available in [44] ) water fraction inhibited urinary and fecal calcium excretion in mature female rats. However, it is noteworthy that the enhancement of calcium absorption by the water fraction was not associated with an increase in serum 1,25-dihydroxyvitamin D 3 levels, but serum parathyroid hormone levels [39] .
Apart from the aged and/or ovariectomized animals, the extract of L. lucidum was found to benefit bone mass acquisition during early life of the animals. Thus, when an ethanol extract of L. lucidum was given to one-month old male and female rats for 4 months, improvements in bone mineral density, bone microarchitecture and bone mechanical properties were observed (compared with control). [64] In addition, L. lucidum treatment increased bone formation marker osteocalcin (OCN), decreased the bone-resorbing marker CTX-1, while increasing serum 25-hydroxyvitamin D 3 . The vitamin D metabolism-and calcium absorption-related gene expressions (1αvitamin D hydroxylase, vitamin D receptor, calcium transporter calbindin-D9K, and transient receptor potential vanilloid 6) were up-regulated. These results suggested that the extract had beneficial effects on peak bone mass acquisition during early life of the animals and the improvement of bone mechanical properties by favoring calcium metabolism [40, 41] .
In diabetic mice, feeding with an aqueous extract of L. lucidum was found to protect against excessive urinary calcium excretion and trabecular bone deterioration. The underlying mechanism might be attributed to the regulation of duodenal calcium transporting proteins and renal calcium-sensing receptor [42] .
The volatile oil obtained from L. lucidum fruits exhibited in vitro osteoblastic activity by stimulating the proliferation and alkaline phosphatase activity of rat calvarial osteoblasts [43] . The main components in the volatile oil included (Z,Z)-9,12-octadecadienoic acid, n-hexadecanoic acid, (E)-9-octadecenoic acid, α-cadinol, 4hexyl-2,5-dihydro-2,5-dioxo-3-furanacetic acid, and (E)-8octadecenoic acid methyl ester [43] . A number of phenylethanoids, secoiridoids, flavonoids and triterpenoids have been identified from 
SECOIRIDOIDS
Oleoside dimethyl ester (7) Promote UMR-106 cell proliferation [61] Oleoside7-ethyl-11-methyl diester (8) Promote UMR-106 cell proliferation [61] Oleuropein (9) Promote UMR-106 cell proliferation; Increase alkaline phosphatase activity in UMR-106 cells [59] Nu(e)zhenide (10) Promote UMR-106 cell proliferation; Increase alkaline phosphatase activity in UMR-106 cells [61] Specnuezhenide (11) Promote UMR-106 cell proliferation; Increase alkaline phosphatase activity in UMR-106 cells [59] G13 (12) Promote UMR-106 cell proliferation; Increase alkaline phosphatase activity in UMR-106 cells [59, 61] FLAVONOIDS Luteolin 7-O-β-D-glucopyranoside (13) Promote UMR-106 cell proliferation; Increase alkaline phosphatase activity in UMR-106 cells [59] Apigenin ( Promote UMR-106 cell proliferation; Increase alkaline phosphatase activity in UMR-106 cells [59] the fruit of L. lucidum and they were summarized in several review articles [44] [45] [46] [47] . Since most of these review articles were published in the Chinese language, the chemical ingredients as highlighted by Huang and Wang [44] are listed in Table 1 .
In recent years, further phenylethanoids, triterpenoids and secoiridoids have been reported and they are included in Table 2 . Several ingredients of L. lucidum fruits have been demonstrated to display potential anti-osteoporosis activities in cell-based and/or animal models. Thus, oleanolic acid (1) and its glycosidic and synthetic derivatives have been known to be inhibitors of osteoclast formation [48] [49] [50] [51] . They inhibited the formation of osteoclast-like multinucleated cells induced by 1α, 25-dihydroxyvitamin D 3 . Oleanolic acid acetate was demonstrated to inhibit receptor activator of nuclear factor-κB (RANKL)-induced osteoclast differentiation; and it attenuated lipopolysaccharide-induced bone erosion in mice [52] . Apart from the anti-osteoclastogenic activity, oleanolic acid was found to be able to promote osteoblastic differentiation and change the gene expression profile of bone marrow stromal cells obtained from rats with corticosteroneinduced osteoporosis [53] . In ovariectomized rats, oleanolic acid exerted osteoprotective effect by increasing the population of osteoblasts as well as the levels of osteocalcin and the Runt-related protein-2. It also stimulated the osteoblastic differentiation of bone mesenchymal stem cells in vitro. Gene expression profile analysis suggested that the effect might be related to the Notch signaling pathway [54] .
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Another triterpene ingredient of L. lucidum, ursolic acid (2), has been found to stimulate osteoblast differentiation and mineralization by activating osteoblast-specific genes such as mitogen-activated protein kinases, nuclear factor-κB, and activator protein-1 [55] . It also promoted bone formation in a mouse calvarial bone formation model [55] . In addition, recent studies showed that ursolic acid was able to inhibit RANKL-induced osteoclast differentiation [56] [57] [58] and down-regulate the NFATc1-regulated osteoclast marker genes [58] . Using a mouse model of titanium particle-induced osteolysis, ursolic acid protected calvarial bone loss and decreased the population of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts [58] .
Two screening and bioactivity-guided isolation reports on the osteoprotective activity of L. lucidum have identified fourteen active compounds [59, 61] . While the screening results are considered to be preliminary at this time, the active compounds were found to promote the proliferation of osteoblast-like UMR-106 cells, increase the alkaline phosphatase activity, and/or protect the cells from hydrogen peroxide-induced damage ( Table 3 ). The chemical structures of these osteo-active compounds are shown in Figure 1 .
Among the four active phenylethanoids, tyrosol (3) and hydroxytyrosol (4) are also present in olive oil [69] [70] [71] , which has been reported to possess anti-osteoporosis property when tested in ovariectomized rats [72] . Salidroside (5) is a major bioactive ingredient of Rhodiola plants and is well known for its adaptogenic potential for use in high-altitude environment [73, 74] . The inhibitory effect of this compound on diabetes-related osteoporosis has been described [75] . Acteoside (6) , also known as verbascoside, is a phenylethanoid glycoside possessing pharmacologically beneficial properties such as antioxidant, anti-inflammatory, antitumor, and neuroprotective activities [76, 77] .
For the secoiridoids, oleuropein (9) is also present in olive oil [69] [70] [71] . Together with the phenylethanoids, it is considered to be the active principle. The structure of specnuezhenide (11) differs from nu(e)zhenide (10) by replacing the glucose with galactose. Both compounds were demonstrated to possess proliferative activity in the osteoblast-like UMR-106 cells and they enhanced the alkaline phosphatase activity [59, 61] . Compound GI 3 (12) can be considered as a dimeric derivative of nu(e)zhenide; it displayed similar in vitro activities. It is noteworthy that nu(e)zhenide (10), specnuezhenide (11) and GI 3 (12) contain the salidroside moiety in their structures. It will, therefore, be of interest to determine whether the salidroside portion of the molecule acts as a pharmacophore for the osteoprotective activity.
The flavonoids apigenin (14) and two glucoside derivatives (15 and 16), as well as luteolin 7-O-β-D-glucopyranoside (13) , were found to be active in UMR-106 cells [59, 61] .
All in all, available information strongly suggests that the fruit of Ligustrum lucidum possesses osteoprotective property and it may be useful in promoting bone health. The beneficial effects seem to be associated with improved calcium balance, modulation of vitamin D metabolism, as well as osteoblastogenic and anti-osteoclastogenic activities. Yet the exact mechanisms remain to be elucidated. Further studies on the potentials of this plant drug and its chemical ingredients for use in the improvement of age-related changes in calcium homeostasis and development of anti-osteoporosis remedies are warranted.
